| Payal Dhar, Fahmin Basher, Zhe Ji, Lei Huang, Si Qin, Jerid Robinson, Jing Zhou, Jennifer D. Wu | Tumor-secreted soluble NKG2D ligand sMIC selectively activates CBM signalosome and polarizes NK cells to a pro-inflammatory phenotype. Commun Biol. 2021 Jul 22;4(1):905. https://www.ncbi.nlm.nih.gov/pubmed/32517713 | 2021 |
| Kristin Wallace, Georges Nahhas, Christine Bookhout, Jessica Thaxton, David Lewin, Nana Nikolaishvili-Feinberg, Stephanie Cohen, J. Grant Brazeal, Elizabeth Hill, Jennifer Wu, John Baron, and Alexander Alekseyenko | Immune responses vary in preinvasive colorectal lesions by tumor location and histology. Cancer Prevention Research (in press) | 2021 |
| Desai AS, Sagar V, Lysy B, Weiner AB, Ko OS, Driscoll C, Rodriguez Y, Vatapalli R, Unno K, Han H, Cohen JE, Vo AX, Pham M, Shin M, Jain-Poster K, Ross J, Morency EG, Meyers TJ, Witte JS, Wu J, Abdulkadir SA, Kundu SD | Inflammatory bowel disease induces inflammatory and pre-neoplastic changes in the prostate. Prostate Cancer Prostatic Disease. 2021 May 25. doi: 10.1038/s41391-021-00392-7. Online ahead of print | 2021 |
| Wallace K, Nahhas GJ, Bookhout C, Lewin DN, Paulos CM, Nikolaishvili-Feinberg N, Cohen SM, Guglietta S, Bakhtiari A, Camp ER, Hill EG, Baron JA, Wu JD, Alekseyenko AV | Preinvasive Colorectal Lesions of African Americans Display an Immunosuppressive Signature Compared to Caucasian Americans. Front Oncol. 2021 April 27, 11:659036. https://www.ncbi.nlm.nih.gov/pubmed/33987094 | 2021 |
| Ronen Sumagin, Lisa Wiesmüller, Jennifer Wu, Guang-Yu Yang, Triet Bui, Veronika Butin-Israeli, Hannah Wiesolek, Meredith Zhou, Jake Rehring, Stephen Hanauer, and Julien Sebag | Neutrophils modulate the DNA damage repair landscape to impact survival and shape distinct therapeutic phenotypes of colorectal cancer. Gastroenterology. 2021 Mar 19;S0016-5085(21)00536-9 | 2021 |
| Adam Weiner, Thiago Vidotto, Seagle Liu, Adrianna Mendes, Daniela C. Salles, Farzana Faisal, Sanjana Murali, Matthew McFarlane, Eddie Imada, Xin Zhao, Ziwen Li, Elai Davicioni, Luigi Marchionni, Arul Chinnaiyan, Stephen Freedland, Daniel Spratt, Jennifer Wu, Tamara Lotan, and Edward Schaeffer | Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes. Nature communications. Nat Commun. 2021 Feb 10;12(1):935 | 2021 |
| Jennifer Wu | Could harnessing NK cell activity be a promising therapy for prostate cancer? Critical Review Immunology. 2021 Volume 41, issue 2. (Invited Review) | 2021 |
| Sizhe Lu, Annie Lee, Vasil Galat, Katya Galat, Jennifer Wu | NK cell-based cancer immunotherapy: from basic biology to clinical development. J Hematol Oncol. 2021 Jan 6;14(1):7. (invited Review) | 2021 |
| Zhai L, Bell A, Ladomersky E, Lauing KL, Bollu L, Sosman JA, Zhang B, Wu JD, Miller SD, Meeks JJ, Lukas RV, Wyatt E, Doglio L, Schiltz GE, McCusker RH, Wainwright DA | Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies. Front Immunol. 2020 Jun 16;11:1185. doi: 10.3389/fimmu.2020.01185. eCollection https://www.ncbi.nlm.nih.gov/pubmed/32612606 | 2020 |
| Fahmin Basher; Payal Dhar; Xin Wang; Derek A Wainwright; Bin Zhang; Jeffrey Sosman; Zhe Ji; Jennifer Wu | Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy. Journal of Hematology & Oncology. 2020 Jun 9;13(1):74. https://www.ncbi.nlm.nih.gov/pubmed/32517713 | 2020 |
| Zhai L, Bell A, Ladomersky E, Lauing KL, Bollu L, Sosman JA, Zhang B, Wu JD, Miller SD, Meeks JJ, Lukas RV, Wyatt E, Doglio L, Schiltz GE, McCusker RH, Wainwright DA | Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies. Front Immunol. 2020 Jun 16;11:1185. https://www.ncbi.nlm.nih.gov/pubmed/32612606 | 2020 |
| Ladomersky E, Zhai L, Lauing KL, Bell A, Xu J, Kocherginsky M, Zhang B, Wu JD, Podojil JR, Platanias LC, Mochizuki AY, Prins RM, Kumthekar P, Raizer J, Dixit K, Lukas RV, Horbinski C, Wei M, Zhou C, Pawelec G, Campisi J, Grohmann U, Prendergast GC, Munn D, Wainwright DA | Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma. Clin Cancer Res. 2020 Jun 16. https://www.ncbi.nlm.nih.gov/pubmed/32546647 | 2020 |
| Roh M, Wainwright DA, Wu JD, Wan Y, Zhang B | Targeting CD73 to augment cancer immunotherapy. Curr Opin Pharmacol. 2020 Aug 7;53:66-76. https://www.ncbi.nlm.nih.gov/pubmed/32777746 | 2020 |
| Meyers TJ, Weiner AB, Graff RE, Desai AS, Cooley LF, Catalona WJ, Hanauer SB, Wu JD, Schaeffer EM, Abdulkadir SA, Kundu SD, Witte JS | Association between inflammatory bowel disease and prostate cancer: A large-scale, prospective, population-based study. Int J Cancer. 2020 May 13. PubMed https://www.ncbi.nlm.nih.gov/pubmed/32399975 | 2020 |
| Chen, S. et al. | CD73: an emerging checkpoint for cancer immunotherapy. Immunotherapy 11, 983–997. https://www.ncbi.nlm.nih.gov/pubmed/31223045 | 2019 |
| Boettcher, A. N. et al. | Past, current, and future of immunotherapies for prostate cancer. Front. Oncol. 9: 884. https://www.frontiersin.org/articles/10.3389/fonc.2019.00884/full | 2019 |
| Ladomersky, E. et al. | The Coincidence Between Increasing Age, Immunosuppression, and the Incidence of Patients With Glioblastoma. Front. Pharmacol. 10, 200. https://www.frontiersin.org/articles/10.3389/fphar.2019.00200/full | 2019 |
| Munoz, D. P. et al. | Targetable mechanisms driving immunoevasion of persistent senescent cells link chemotherapy-resistant cancer to aging. JCI insight 5. https://www.ncbi.nlm.nih.gov/pubmed/31184599 | 2019 |
| Liu, S., Dhar, P. & Wu, J. D. | NK Cell Plasticity in Cancer. J. Clin. Med. 8. https://www.ncbi.nlm.nih.gov/pubmed/31546818 | 2019 |
| Drake, R. R., Angel, P. M., Wu, J., Pachynski, R. K. & Ippolito, J. E. | How else can we approach prostate cancer biomarker discovery? Expert Rev. Mol. Diagn. 1–3. doi:10.1080/14737159.2019.1665507 https://www.ncbi.nlm.nih.gov/pubmed/31498690 | 2019 |
| Zhang, J. et al. | Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC+ tumors to respond to PD1/PD-L1 blockade therapt. J. Immunother. Cancer In Press. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709558/ | 2019 |
| Wallace, K. et al. | Tumor-Infiltrating Lymphocytes and Colorectal Cancer Survival in African American and Caucasian Patients. Cancer Epidemiol. Biomarkers Prev. 27, 755–761. https://www.ncbi.nlm.nih.gov/pubmed/29769214 | 2018 |
| Dhar, P. & Wu, J. D. | NKG2D and its ligands in cancer. Curr. Opin. Immunol. 51, 55–61. https://www.ncbi.nlm.nih.gov/pubmed/29525346 | 2018 |
| Chatterjee, S. et al. | CD38-NAD(+)Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response. Cell Metab. 27, 85-100.e8. https://www.ncbi.nlm.nih.gov/pubmed/29129787 | 2018 |
| Liu, G. et al. | Prostate-specific IL-6 transgene autonomously induce prostate neoplasm through amplifying inflammation in the prostate and peri-prostatic adipose tissue. J. Hematol. Oncol. 10, 14. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225646/ | 2017 |
| Zhang, J. et al. | Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy. Sci. Adv. 3, e1602133. https://www.ncbi.nlm.nih.gov/pubmed/28560327 | 2017 |
| Wu, J. | Antibody targeting soluble NKG2D ligand sMIC refuels and invigorates the endogenous immune system to fight cancer. Oncoimmunology 5, e1095434. https://www.ncbi.nlm.nih.gov/pubmed/27141357 | 2016 |
| Basher, F., Jeng, E. K., Wong, H. & Wu, J. | Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and co-targeting soluble NKG2D ligand sMIC. Oncotarget 7, 814–830. https://www.ncbi.nlm.nih.gov/pubmed/26625316 | 2016 |
| Liu, Q. et al. | The CXCL8-CXCR1/2 pathways in cancer. Cytokine Growth Factor Rev. 31, 61–71. https://www.ncbi.nlm.nih.gov/pubmed/27578214 | 2016 |
| Zhang, J., Basher, F. & Wu, J. D. | NKG2D Ligands in Tumor Immunity: Two Sides of a Coin. Front. Immunol. 6, 97. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4349182/ | 2015 |
| Lu, S. et al. | Nonblocking Monoclonal Antibody Targeting Soluble MIC Revamps Endogenous Innate and Adaptive Antitumor Responses and Eliminates Primary and Metastatic Tumors. Clin. Cancer Res. 21, 4819–4830. https://www.ncbi.nlm.nih.gov/pubmed/26106076 | 2015 |
| Xiao, G. et al. | Soluble NKG2D ligand promotes MDSC expansion and skews macrophage to the alternatively activated phenotype. J. Hematol. Oncol. 8, 13. https://www.ncbi.nlm.nih.gov/pubmed/25887583 | 2015 |